Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600436 | 0.89 | USP2 (0.40) | USP2SMN1; SMN2ESR2CTSKNR1H2 | |
| SCHEMBL31552232 | 0.87 | HPGD (0.40) | USP2SMN1; SMN2ESR2CTSKNR1H2 | |
| SCHEMBL31551926 | 0.86 | HPGD (0.42) | USP2SMN1; SMN2ESR2CTSKNR1H2 | |
| SCHEMBL20265001 | 0.82 | USP2 (0.46) | USP2SMN1; SMN2ESR2CTSKNR1H2 | |
| SCHEMBL16096089 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2ESR2CTSKNR1H2 | |
| SCHEMBL31058789 | 0.81 | USP2 (0.33) | USP2SMN1; SMN2GPR119MEN1KMT2A | |
| SCHEMBL4196209 | 0.78 | — | — | |
| SCHEMBL900813 | 0.78 | USP2 (0.37) | USP2SMN1; SMN2ESR2CTSKNR1H2 | |
| SCHEMBL4773530 | 0.76 | USP2 (0.58) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL6023105 | 0.74 | CTSK (0.50) | USP2SMN1; SMN2ESR2CTSKNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114524811-B | LXH0307 and LXH0308 as small molecule inhibitors for gene editing and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2025-01-24 | — | — | CN | claimed |
| CN-114685494-B | Synthetic preparation method and application of SpCas9 inhibitor | 中国人民解放军军事科学院军事医学研究院 | 2024-04-16 | — | — | CN | claimed |
| CN-114685494-A | Synthesis preparation method and application of SpCas9 inhibitor | 中国人民解放军军事科学院军事医学研究院 | 2022-07-01 | — | — | CN | claimed |
| CN-114524811-A | LXH0307 and LXH0308 as small molecule inhibitors of gene editing and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-05-24 | — | — | CN | claimed |
| US-12617803-B2 | Condensed isoxazoline derivatives and their use as herbicides | BASF SE (DE) | 2026-05-05 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025132946-A1 | PHENYLPYRROLIDINE DERIVATIVES AND THEIR USE AS POI-THETA DERIVATIVES | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119930869-A | Auxiliary agent for olefin polymerization, olefin catalyst system, prepolymerized catalyst composition and olefin polymerization method | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930872-A | Catalyst system, prepolymerized catalyst composition and olefin polymerization process | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115515962-B | Fused isoxazoline derivatives and their use as herbicides | 巴斯夫欧洲公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2004076464-A2 | OPTICALLY ACTIVE PHOSPHITES AND PHOSPHORAMIDITES AND THEIR USE IN ASYMMETRIC REACTIONS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-09-10 | — | — | WO | disclosed |
| EP-1165509-A1 | METHOD OF PRODUCING 3,4-DIHYDROPROLINES AND 3,4-DEHYDROPIPERIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| WO-2000058284-A1 | METHOD OF PRODUCING 3,4-DIHYDROPROLINES AND 3,4-DEHYDROPIPERIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-05 | — | — | WO | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | USP2 2642/4885SMN1; SMN2 4806/4885ESR2 4165/4885 |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB4 | USP2 2464/4885SMN1; SMN2 4686/4885ESR2 129/4885 |
| US-12617803-B2 | Condensed isoxazoline derivatives and their use as herbicides | CBR3, CBR1, GLRA3 | USP2 4141/4885SMN1; SMN2 4844/4885ESR2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.